MARKET

COCP

COCP

Cocrystal Pharma Inc
NASDAQ
0.9900
-0.0100
-1.00%
Pre Market: 0.9900 0 0.00% 09:03 12/22 EST
OPEN
0.9900
PREV CLOSE
1.000
HIGH
1.040
LOW
0.9800
VOLUME
39
TURNOVER
0
52 WEEK HIGH
3.260
52 WEEK LOW
0.9000
MARKET CAP
13.65M
P/E (TTM)
-1.0581
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at COCP last week (1215-1219)?
Weekly Report · 4h ago
Cocrystal Pharma gains IRB approval for norovirus trial
TipRanks · 3d ago
Cocrystal Pharma receives IRB approval from Emory University for Phase 1b trial
TipRanks · 4d ago
Cocrystal Pharma Receives IRB Approval for Phase 1b Norovirus Study
Reuters · 4d ago
COCRYSTAL PHARMA RECEIVES IRB APPROVAL FROM EMORY UNIVERSITY SCHOOL OF MEDICINE FOR PHASE 1B HUMAN CHALLENGE STUDY WITH CDI-988 FOR PREVENTION AND TREATMENT OF NOROVIRUS
Reuters · 4d ago
COCRYSTAL PHARMA INC - SUBJECT ENROLLMENT FOR STUDY EXPECTED TO BEGIN IN Q1 2026
Reuters · 4d ago
Weekly Report: what happened at COCP last week (1208-1212)?
Weekly Report · 12/15 09:30
Weekly Report: what happened at COCP last week (1201-1205)?
Weekly Report · 12/08 09:30
More
About COCP
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.

Webull offers Cocrystal Pharma Inc stock information, including NASDAQ: COCP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COCP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading COCP stock methods without spending real money on the virtual paper trading platform.